Yüksel Ürün: Cancer screening with multicancer detection tests

Yüksel Ürün shared a post on X:

“Multicancer Detection (MCD) tests use one blood sample to screen for multiple cancers.

• Potentially improves early detection, especially for cancers without effective screening.
• Benefits and harms are still unknown.
• Unlike conventional tests, the specific cancer organ is unknown, requiring broad diagnostics.
• In studies with 16,000+ participants, MCD identified early-stage cancers like pancreas, ovary, liver, and more.
• Sensitivity ranges from 27%-95%, lower for early-stage cancers.
• False negatives may reduce standard screening adherence.
• Trials needed to confirm accuracy, early detection effectiveness, and impact on overdiagnosis.”

Additional information.
Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.